Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free SMMT Stock Alerts

Summit Therapeutics (SMMT) Financials

Summit Therapeutics logo
$18.14 -0.65 (-3.46%)
Closing price 04:00 PM Eastern
Extended Trading
$18.14 0.00 (-0.03%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Summit Therapeutics

Annual Income Statements for Summit Therapeutics

This table shows Summit Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/31/2016 1/31/2017 1/31/2018 1/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -38 -27 -29 11 -53 -89 -79 -615 -221 -1,080
Consolidated Net Income / (Loss)		 -29 -27 -29 11 -53 -89 -79 -615 -221 -1,080
Net Income / (Loss) Continuing Operations		 -38 -27 -29 11 -53 -89 -79 -615 -221 -1,080
Total Pre-Tax Income 		-33 -33 -34 9.08 -53 -89 -76 -615 -221 -1,080
Total Operating Income		 -29 -31 -32 5.39 -53 -86 -72 -610 -226 -1,094
Total Gross Profit		 -29 -31 -37 57 0.86 1.81 0.71 0.00 0.00 0.00
Total Revenue		 0.00 3.02 26 57 0.86 1.81 0.71 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 29 34 58 52 54 88 73 610 226 1,094
Selling, General & Admin Expense		 6.89 10 17 17 19 24 27 29 60 557
Research & Development Expense		 24 24 41 52 53 85 52 580 166 538
Total Other Income / (Expense), net		 -4.11 -1.09 -1.69 3.69 0.28 -2.42 -4.40 -5.28 4.68 15
Interest Expense		 4.16 - - - - - 4.40 16 8.69 0.00
Other Income / (Expense), net		 - -1.09 -1.69 3.69 0.28 -2.42 - 11 13 15
Basic Earnings per Share		 - - - $0.63 ($0.76) ($0.67) ($0.41) ($0.99) ($0.31) ($1.44)
Weighted Average Basic Shares Outstanding		 - - 73.56M 17.14M 69.52M 131.71M 193.34M 619.65M 718.54M 747.70M
Diluted Earnings per Share		 - - - $0.63 ($0.76) ($0.67) ($0.41) ($0.99) ($0.31) ($1.44)
Weighted Average Diluted Shares Outstanding		 - - 73.56M 17.23M 69.52M 131.71M 193.34M 619.65M 718.54M 747.70M
Weighted Average Basic & Diluted Shares Outstanding		 - - 73.56M 160.39M 82.92M 98.12M 697.69M 701.70M 737.68M 775.37M

Quarterly Income Statements for Summit Therapeutics

This table shows Summit Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -21 -36 -43 -60 -56 -61 -63 -566 -232 -219 -189
Consolidated Net Income / (Loss)		 -21 -37 -43 -60 -56 -61 -63 -566 -232 -219 -189
Net Income / (Loss) Continuing Operations		 -21 -37 -43 -60 -56 -61 -63 -566 -232 -219 -189
Total Pre-Tax Income 		-21 -48 -43 -63 -61 -75 -63 -568 -234 -214 -189
Total Operating Income		 -20 -36 -42 -60 -58 -66 -67 -568 -234 -225 -195
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 20 36 42 60 58 66 67 568 234 225 195
Selling, General & Admin Expense		 5.43 12 12 14 21 14 16 360 103 78 63
Research & Development Expense		 15 25 31 46 38 51 51 208 131 147 133
Total Other Income / (Expense), net		 -0.78 -12 -1.08 -3.10 -2.45 -8.96 3.94 0.00 0.00 11 5.79
Other Income / (Expense), net		 -0.78 - 2.04 - - - 3.94 - - - 5.79
Basic Earnings per Share		 ($0.03) $0.49 ($0.06) ($0.09) ($0.08) ($0.08) ($0.09) ($0.76) ($0.31) ($0.28) ($0.24)
Weighted Average Basic Shares Outstanding		 697.74M 619.65M 701.79M 707.90M 726.66M 718.54M 738.08M 742.62M 743.42M 747.70M 775.46M
Diluted Earnings per Share		 ($0.03) $0.49 ($0.06) ($0.09) ($0.08) ($0.08) ($0.09) ($0.76) ($0.31) ($0.28) ($0.24)
Weighted Average Diluted Shares Outstanding		 697.74M 619.65M 701.79M 707.90M 726.66M 718.54M 738.08M 742.62M 743.42M 747.70M 775.46M
Weighted Average Basic & Diluted Shares Outstanding		 700.84M 701.70M 701.98M 724.54M 737.45M 737.68M 742.67M 742.85M 744.44M 775.37M 776.16M

Annual Cash Flow Statements for Summit Therapeutics

This table details how cash moves in and out of Summit Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/31/2016 1/31/2017 1/31/2018 1/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 7.10 16 -8.59 9.07 2.58 5.37 577 -577 34 120
Net Cash From Operating Activities		 -25 15 -21 -35 -48 -73 -42 -77 -142 -323
Net Cash From Continuing Operating Activities		 -26 15 -20 -35 -48 -73 -42 -77 -142 -323
Net Income / (Loss) Continuing Operations		 -33 -33 -34 11 -53 -89 -79 -615 -221 -1,080
Consolidated Net Income / (Loss)		 -33 -33 -34 11 -53 -89 -79 -615 -221 -1,080
Depreciation Expense		 0.05 0.06 0.42 0.41 0.30 0.33 0.35 0.20 0.09 0.15
Amortization Expense		 - - - 1.10 1.70 2.13 0.91 -1.92 -2.58 -7.01
Non-Cash Adjustments To Reconcile Net Income		 5.54 3.74 2.28 7.86 2.07 14 26 540 66 732
Changes in Operating Assets and Liabilities, net		 1.53 44 12 -55 0.52 -0.07 9.72 -0.16 16 31
Net Cash From Investing Activities		 -0.05 -0.10 -7.48 -0.33 -0.42 -0.31 -0.62 -588 -205 -174
Net Cash From Continuing Investing Activities		 -0.05 -0.10 -0.67 -0.33 -0.42 -0.31 -0.62 -588 -205 -174
Purchase of Property, Plant & Equipment		 -0.10 -0.11 -0.68 -0.16 -0.42 -0.31 -0.62 -0.13 -0.14 -0.66
Purchase of Investments		 - - - - - - 0.00 -321 -680 -485
Sale of Property, Plant & Equipment		 - - - - - - 0.00 0.23 0.00 0.00
Sale and/or Maturity of Investments		 - - - - - - 0.00 208 490 311
Other Investing Activities, net		 0.04 0.01 0.02 -0.17 - - - -475 -15 0.00
Net Cash From Financing Activities		 32 0.52 20 45 51 78 620 87 381 618
Net Cash From Continuing Financing Activities		 32 0.52 20 45 51 78 620 87 381 618
Repayment of Debt		 - - -0.18 - 0.00 -110 -25 -25 -100 0.00
Repurchase of Common Equity		 -6.04 0.00 -2.04 -1.71 -0.05 -0.12 -0.11 -0.62 0.00 0.00
Issuance of Common Equity		 38 0.00 21 46 50 75 100 111 481 610
Other Financing Activities, net		 0.32 0.49 0.57 0.13 0.60 3.09 0.00 1.20 0.60 7.32
Effect of Exchange Rate Changes		 - - - - 0.56 0.35 - 0.84 -0.02 0.10
Cash Interest Paid		 - - - - 0.00 0.09 0.43 11 8.81 0.00
Cash Income Taxes Paid		 - - - 0.07 -0.07 - 0.00 0.05 0.00 0.00

Quarterly Cash Flow Statements for Summit Therapeutics

This table details how cash moves in and out of Summit Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -18 47 -9.81 -33 65 11 107 86 -59 -13 -119
Net Cash From Operating Activities		 -15 -19 -30 -33 -30 -49 -61 -67 -93 -102 -122
Net Cash From Continuing Operating Activities		 -15 -19 -30 -33 -30 -49 -61 -67 -93 -102 -122
Net Income / (Loss) Continuing Operations		 -21 -37 -43 -60 -56 -61 -63 -566 -232 -219 -189
Consolidated Net Income / (Loss)		 -21 -37 -43 -60 -56 -61 -63 -566 -232 -219 -189
Depreciation Expense		 0.03 0.03 0.03 0.02 0.02 0.02 0.03 0.04 0.04 0.04 0.04
Amortization Expense		 1.19 -0.21 -0.40 -1.61 -2.92 2.35 -2.97 -1.02 - -3.02 -4.22
Non-Cash Adjustments To Reconcile Net Income		 0.97 8.34 9.42 26 20 11 11 479 131 112 73
Changes in Operating Assets and Liabilities, net		 4.19 8.95 4.29 3.16 8.93 -0.73 -6.21 21 7.93 8.07 -2.04
Net Cash From Investing Activities		 -3.49 61 20 -200 -109 83 160 151 -0.07 -485 -0.24
Net Cash From Continuing Investing Activities		 -3.49 61 20 -200 -109 83 160 151 -0.07 -485 -0.24
Purchase of Property, Plant & Equipment		 -0.05 -0.00 -0.00 -0.06 -0.06 -0.01 -0.42 - -0.07 -0.16 -0.25
Purchase of Investments		 -113 0.00 -93 -270 -168 -149 0.00 - - -485 -177
Sale and/or Maturity of Investments		 109 61 113 70 74 233 161 151 - - 177
Net Cash From Financing Activities		 0.23 6.25 0.49 200 204 -24 7.68 2.22 34 574 3.80
Net Cash From Continuing Financing Activities		 0.23 6.25 0.49 200 204 -24 7.68 2.22 34 574 3.80
Issuance of Common Equity		 -0.39 5.67 0.49 200 280 0.39 2.02 0.57 34 574 3.80
Other Financing Activities, net		 - 1.20 0.00 - - 0.50 5.66 1.66 - - 0.00
Effect of Exchange Rate Changes		 -0.17 - -0.04 0.01 0.11 - - 0.06 0.02 -0.02 -0.02

Annual Balance Sheets for Summit Therapeutics

This table presents Summit Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/31/2017 1/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 48 77 96 102 113 664 203 436 751
Total Current Assets		 42 51 80 88 97 657 190 424 720
Cash & Equivalents		 36 29 64 66 72 349 71 105 225
Restricted Cash		 - - - - 0.00 300 0.00 0.33 0.32
Short-Term Investments		 - - - - - 0.00 115 307 488
Prepaid Expenses		 - - 8.76 9.55 7.16 1.50 2.62 11 6.54
Plant, Property, & Equipment, net		 94 1.15 0.52 0.73 0.69 0.91 0.20 0.25 1.06
Total Noncurrent Assets		 5.23 25 16 14 15 6.55 13 12 30
Goodwill		 0.84 3.53 1.96 2.03 2.01 1.80 1.89 1.86 2.00
Other Noncurrent Operating Assets		 - - 1.02 0.55 2.96 4.75 11 9.69 28
Total Liabilities & Shareholders' Equity		 141 73 96 102 113 664 203 436 751
Total Liabilities		 52 82 17 23 30 538 125 47 92
Total Current Liabilities		 14 32 14 20 26 39 20 42 73
Accounts Payable		 5.04 13 4.47 6.14 4.37 0.36 2.67 4.64 20
Accrued Expenses		 - - 5.74 3.28 7.20 11 8.78 20 32
Current Employee Benefit Liabilities		 - - - 0.98 4.13 5.64 5.43 12 15
Other Current Liabilities		 - 20 0.84 1.12 1.99 2.35 3.53 5.56 5.67
Total Noncurrent Liabilities		 97 49 3.62 3.16 4.47 499 105 5.08 19
Other Noncurrent Operating Liabilities		 66 41 3.13 2.59 4.47 4.19 4.85 5.08 19
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 30 -4.54 79 79 83 127 78 389 659
Total Preferred & Common Equity		 30 -4.54 79 79 83 127 78 389 659
Preferred Stock		 - 86 - - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 30 -90 79 79 83 127 78 389 659
Common Stock		 0.78 1.05 242 294 385 507 1,073 1,606 2,956
Retained Earnings		 - -134 -158 -211 -300 -378 -993 -1,215 -2,294
Accumulated Other Comprehensive Income / (Loss)		 - - -4.76 -3.79 -2.20 -1.89 -2.45 -2.29 -2.54

Quarterly Balance Sheets for Summit Therapeutics

This table presents Summit Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 155 255 237 218 177 342 503 384 324 262 648
Total Current Assets		 137 248 228 205 163 329 490 371 309 246 617
Cash & Equivalents		 122 71 42 24 61 28 94 212 298 239 107
Restricted Cash		 - 0.00 0.00 0.00 0.32 0.32 0.32 0.32 0.32 0.32 0.32
Short-Term Investments		 - 171 173 175 95 297 393 150 0.00 0.00 492
Prepaid Expenses		 1.62 1.19 6.09 5.07 5.32 2.05 2.41 9.12 11 7.59 18
Plant, Property, & Equipment, net		 0.93 0.41 0.23 0.23 0.18 0.22 0.27 0.65 0.69 0.81 1.66
Total Noncurrent Assets		 17 6.46 9.65 13 13 13 12 12 14 14 30
Goodwill		 1.66 1.84 1.88 1.81 1.88 1.88 1.99 1.92 2.04 2.00 1.97
Other Noncurrent Operating Assets		 7.67 4.08 7.76 11 11 11 10 10 12 12 28
Total Liabilities & Shareholders' Equity		 155 255 237 218 177 342 503 384 324 262 648
Total Liabilities		 22 121 118 119 133 147 65 39 65 69 102
Total Current Liabilities		 17 17 12 114 23 140 59 35 60 65 83
Accounts Payable		 1.43 0.71 0.99 3.31 6.37 3.34 3.25 4.99 23 22 28
Accrued Expenses		 11 12 3.87 3.65 6.55 27 18 21 26 27 44
Current Employee Benefit Liabilities		 2.51 2.42 3.53 3.51 6.03 4.88 7.96 4.40 6.59 11 7.07
Other Current Liabilities		 1.60 2.01 3.55 3.26 4.49 4.49 4.82 4.30 4.60 4.68 4.33
Total Noncurrent Liabilities		 5.40 104 106 5.36 109 6.61 5.92 4.62 4.27 4.54 19
Other Noncurrent Operating Liabilities		 5.40 3.97 5.84 5.36 9.13 6.61 5.92 4.62 4.27 4.54 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 133 133 120 99 44 195 438 344 259 192 546
Total Preferred & Common Equity		 133 133 120 99 44 195 438 344 259 192 546
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 133 133 120 99 44 195 438 344 259 192 546
Common Stock		 496 1,056 1,057 1,058 1,083 1,295 1,594 1,624 2,105 2,270 3,032
Retained Earnings		 -359 -921 -935 -957 -1,037 -1,097 -1,153 -1,277 -1,843 -2,075 -2,484
Accumulated Other Comprehensive Income / (Loss)		 -3.22 -1.40 -2.44 -2.32 -2.45 -2.50 -2.31 -2.56 -2.75 -2.71 -2.63

Annual Metrics And Ratios for Summit Therapeutics

This table displays calculated financial ratios and metrics derived from Summit Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/31/2016 1/31/2017 1/31/2018 1/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 759.29% 120.15% -98.49% 110.35% -61.03% -100.00% 0.00% 0.00%
EBITDA Growth		 0.00% -10.81% -3.75% 131.43% -580.62% -69.22% 17.78% -763.21% 62.63% -405.05%
EBIT Growth		 0.00% -10.81% -4.84% 126.62% -682.52% -67.46% 18.64% -745.69% 62.93% -407.73%
NOPAT Growth		 0.00% -7.10% -3.10% 128.41% -677.41% -62.03% 16.36% -745.69% 62.93% -384.26%
Net Income Growth		 0.00% 6.92% -6.28% 137.80% -584.84% -68.13% 11.08% -680.54% 64.01% -387.81%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -220.63% 11.84% 38.81% -141.46% 68.69% -364.52%
Operating Cash Flow Growth		 0.00% 161.97% -234.94% -69.28% -37.04% -50.87% 42.71% -84.60% -85.13% -127.25%
Free Cash Flow Firm Growth		 0.00% 0.00% 104.69% -4,893.20% 6.24% -67.27% 46.71% -1,259.39% 66.46% -414.71%
Invested Capital Growth		 0.00% 0.00% -440.78% 152.51% -13.82% -11.84% -166.50% -11.87% -179.84% -129.47%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 3.79% -26.26% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -24.39% 5.88% -2.81% -14.32% -16.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -23.58% 7.38% -2.68% -14.91% -15.45%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -20.21% 7.38% -2.68% -14.96% -17.04%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -18.07% 9.08% -2.90% -12.53% -17.14%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 22.09% -13.89% 34.87% -219.23% -16.13%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 21.62% -1.69% 25.68% -47.30% -25.88% -19.75%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 28.34% -5.21% -27.09% -16.18%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -47.88% -167.78% -2,070.05% 3.52% -17.79%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% -1,042.49% -142.07% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -1,076.30% -129.95% 18.55% -5,919.42% -4,762.13% -10,046.24% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -1,042.16% -125.04% 9.44% -6,185.23% -4,764.29% -10,225.39% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -1,078.31% -131.57% 15.91% -6,152.33% -4,897.84% -10,225.39% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -896.43% -110.87% 19.04% -6,127.56% -4,897.84% -11,174.75% 0.00% 0.00% 0.00%
Tax Burden Percent		 86.82% 83.13% 84.27% 119.66% 99.60% 100.00% 103.00% 98.21% 94.30% 100.00%
Interest Burden Percent		 114.00% 100.00% 100.00% 100.00% 100.00% 100.00% 106.11% 102.70% 103.84% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% -19.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -264.44% -491.91% -2,621.42% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -240.68% -451.00% -2,593.94% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 197.86% 383.02% 2,546.37% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -89.59% -224.14% 29.25% -66.57% -108.89% -75.05% -601.85% -94.90% -206.11%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -247.81% -249.59% -479.33% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -68.39% -54.79% 10.49% -53.24% -82.09% -18.54% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -56.86% -46.17% 12.55% -53.03% -82.09% -20.26% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -89.59% 526.52% -4.56% -66.57% -108.89% -75.05% -601.85% -94.90% -206.11%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -89.59% 633.10% 13.78% -66.32% -106.39% -62.20% -791.49% -56.93% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -22 -23 6.45 -37 -60 -50 -427 -158 -766
NOPAT Margin		 0.00% -729.51% -87.53% 11.30% -4,329.66% -3,335.00% -7,157.77% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -28.36% -20.25% 10.05% -23.76% -40.91% -27.48% -170.65% -25.30% -55.66%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -7.87% -240.17% -40.69% -116.28%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 347.19% 65.65% 29.80% 2,236.28% 1,305.20% 3,793.33% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 794.97% 159.39% 91.09% 6,194.65% 4,718.19% 7,375.74% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 1,142.16% 225.04% 90.56% 6,285.23% 4,864.29% 10,325.39% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -29 -33 -34 9.08 -53 -89 -72 -610 -226 -1,080
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -32 -34 11 -51 -86 -71 -611 -228 -1,086
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 1.24 4.87 3.16 3.29 23.54 33.85 19.76
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 1.53 5.87 3.71 3.34 24.13 34.01 19.82
Price to Revenue (P/Rev)		 0.00 0.00 0.00 1.71 449.56 145.30 591.52 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 9.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 11.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 2.25 24.56 16.62 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.60 372.33 105.62 401.03 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 3.22 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 3.75 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 5.28 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 4.06 1.29 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 3.90 1.29 0.00 0.00
Financial Leverage		 0.00 -1.18 -2.33 -1.18 -0.82 -0.85 -0.98 -1.08 -1.07 -1.08
Leverage Ratio		 0.00 1.58 4.85 2.33 1.26 1.33 3.70 4.24 1.37 1.13
Compound Leverage Factor		 0.00 1.58 4.85 2.33 1.26 1.33 3.93 4.36 1.42 1.13
Debt to Total Capital		 0.00% 0.00% 0.00% 0.13% 0.00% 0.00% 80.24% 56.28% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.13% 0.00% 0.00% 3.08% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 77.16% 56.28% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% -1,891.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 1,991.87% 99.87% 100.00% 100.00% 19.76% 43.72% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.01 0.00 0.00 -7.26 -0.16 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 -6.02 0.00 0.00 1.90 0.14 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -6.98 -0.16 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.02 0.00 0.00 -10.19 -0.23 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 -9.88 0.00 0.00 2.66 0.20 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -9.80 -0.23 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 2.80 6.28 -0.26 0.43 -7.00 164.11 76.63
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 334.90% 115.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 3.06 1.58 5.78 4.41 3.80 16.93 9.30 10.15 9.87
Quick Ratio		 0.00 2.67 1.37 4.68 3.36 2.86 9.00 9.13 9.88 9.77
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -17 0.78 -37 -35 -59 -31 -426 -143 -735
Operating Cash Flow to CapEx		 -26,033.37% 13,796.55% -3,035.49% -22,360.51% -11,427.79% -23,721.24% -6,663.78% 0.00% -102,234.53% -49,152.21%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -7.12 -25.87 -16.44 0.00
Operating Cash Flow to Interest Expense		 -5.97 0.00 0.00 0.00 0.00 0.00 -9.45 -4.66 -16.36 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -5.99 0.00 0.00 0.00 0.00 0.00 -9.59 -4.66 -16.38 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.06 0.42 0.66 0.01 0.02 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 2.32 3.02 6.95 1.97 2.02 0.78 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.03 0.55 68.29 1.38 2.55 0.88 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 157.24 120.91 52.50 185.05 181.09 469.32 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 157.24 120.91 52.50 185.05 181.09 469.32 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -5.33 -29 15 13 11 -7.64 -8.55 -24 -55
Invested Capital Turnover		 0.00 -1.13 -1.52 -8.35 0.06 0.15 0.37 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.33 -23 44 -2.09 -1.54 -19 -0.91 -15 -31
Enterprise Value (EV)		 0.00 0.00 0.00 34 320 191 283 1,743 12,747 12,307
Market Capitalization		 0.00 0.00 0.00 98 387 263 417 1,829 13,160 13,020
Book Value per Share		 $0.00 $0.00 ($1.23) $1.07 $0.97 $0.85 $1.29 $0.11 $0.53 $0.89
Tangible Book Value per Share		 $0.00 $0.00 ($1.56) $0.87 $0.80 $0.73 $1.27 $0.11 $0.52 $0.88
Total Capital		 0.00 30 -4.54 79 79 83 641 178 389 659
Total Debt		 0.00 0.00 0.00 0.11 0.00 0.00 514 100 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 495 100 0.00 0.00
Net Debt		 0.00 -36 -29 -64 -66 -72 -134 -86 -413 -714
Capital Expenditures (CapEx)		 0.10 0.11 0.68 0.16 0.42 0.31 0.62 -0.10 0.14 0.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -7.12 -9.95 2.12 1.37 -0.10 -11 -17 -31 -66
Debt-free Net Working Capital (DFNWC)		 0.00 28 19 66 68 72 638 169 382 647
Net Working Capital (NWC)		 0.00 28 19 66 68 72 618 169 382 647
Net Nonoperating Expense (NNE)		 8.51 5.04 6.05 -4.42 15 28 28 188 63 313
Net Nonoperating Obligations (NNO)		 0.00 -36 -24 -64 -66 -72 -134 -86 -413 -714
Total Depreciation and Amortization (D&A)		 0.05 0.06 0.42 1.51 2.00 2.46 1.26 -1.73 -2.49 -6.86
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -235.78% -38.38% 3.72% 158.95% -5.64% -1,547.09% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 941.32% 72.19% 115.55% 7,881.86% 3,962.91% 90,453.90% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 941.32% 72.19% 115.37% 7,881.86% 3,962.91% 87,649.65% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.76) $0.00 ($0.41) ($0.99) ($0.31) ($1.44)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 73.56M 0.00 69.52M 0.00 193.34M 619.65M 718.54M 747.70M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.76) $0.00 ($0.41) ($0.99) ($0.31) ($1.44)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 73.56M 0.00 69.52M 0.00 193.34M 619.65M 718.54M 747.70M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 73.56M 0.00 82.92M 0.00 697.69M 701.70M 737.68M 775.37M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -22 -23 7.48 -37 -60 -45 -427 -158 -766
Normalized NOPAT Margin		 0.00% -729.51% -87.53% 13.09% -4,259.74% -3,335.00% -6,316.98% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -1,078.31% -131.57% 15.91% -6,152.33% -4,897.84% -10,849.65% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -7.07 0.00 0.00 0.00 0.00 0.00 -16.38 -37.04 -26.02 0.00
NOPAT to Interest Expense		 -4.95 0.00 0.00 0.00 0.00 0.00 -11.47 -25.93 -18.21 0.00
EBIT Less CapEx to Interest Expense		 -7.09 0.00 0.00 0.00 0.00 0.00 -16.52 -37.03 -26.03 0.00
NOPAT Less CapEx to Interest Expense		 -4.97 0.00 0.00 0.00 0.00 0.00 -11.61 -25.92 -18.23 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -20.79% 0.00% -7.08% 15.71% -0.09% -0.13% -0.14% -0.10% 0.00% 0.00%

Quarterly Metrics And Ratios for Summit Therapeutics

This table displays calculated financial ratios and metrics derived from Summit Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 775,372,700.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 775,372,700.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.24
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 3.01% -73.66% 91.91% -252.66% -195.01% -73.80% -61.70% -830.40% -282.15% -260.36% -193.98%
EBIT Growth		 0.55% -78.38% 91.98% -310.31% -164.50% -81.20% -55.91% -853.48% -301.20% -242.80% -201.09%
NOPAT Growth		 -20.97% -78.38% 92.11% -277.47% -184.88% -81.20% -57.71% -853.48% -301.20% -242.80% -192.01%
Net Income Growth		 0.55% -90.17% 91.98% -310.31% -164.50% -67.37% -44.72% -836.84% -312.05% -258.11% -201.09%
EPS Growth		 70.00% 1,325.00% 95.80% -350.00% -166.67% -116.33% -50.00% -744.44% -287.50% -250.00% -166.67%
Operating Cash Flow Growth		 -74.13% -474.86% -129.49% -12.74% -103.38% -150.13% -102.99% -102.24% -207.23% -109.43% -99.93%
Free Cash Flow Firm Growth		 -222.71% -596.07% 92.87% -276.09% -346.41% -25.02% -66.88% -5,960.53% -809.34% -313.92% -138.50%
Invested Capital Growth		 -96.15% -11.87% -51.33% -769.88% -5,814.29% -179.84% -35.32% -26.17% -87.95% -129.47% -206.97%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -14.11% -81.48% -21.23% -41.33% 4.55% -6.91% -4.13% -764.67% 58.88% 2.68% 15.05%
EBIT Q/Q Growth		 -44.51% -70.26% -18.89% -38.90% 6.84% -16.64% 4.12% -803.53% 58.80% 3.96% 15.78%
NOPAT Q/Q Growth		 -29.75% -76.70% -17.06% -40.64% 2.08% -12.40% -1.89% -750.30% 58.80% 3.96% 13.21%
Net Income Q/Q Growth		 -44.51% -71.93% -18.89% -38.90% 6.84% -8.80% -2.79% -799.19% 59.03% 5.44% 13.57%
EPS Q/Q Growth		 -50.00% 1,733.33% -112.24% -50.00% 11.11% 0.00% -12.50% -744.44% 59.21% 9.68% 14.29%
Operating Cash Flow Q/Q Growth		 49.11% -30.62% -54.86% -9.52% 8.20% -60.65% -25.67% -9.12% -39.46% -9.52% -19.97%
Free Cash Flow Firm Q/Q Growth		 -195.84% -598.01% -3.66% 74.61% -142.98% -95.47% -38.38% -822.12% 63.54% 11.02% 20.27%
Invested Capital Q/Q Growth		 -90.53% -2,070.05% -49.56% -140.20% 19.26% 3.52% 27.68% -123.96% -20.28% -17.79% 3.26%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 76.58% 100.00% 100.00% 100.00% 82.07% 100.00% 99.52% 98.97% 102.40% 100.00%
Interest Burden Percent		 100.00% 131.87% 100.00% 100.00% 100.00% 113.65% 100.00% 100.00% 100.00% 95.15% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -513.78% -601.85% -130.59% -102.77% -73.21% -94.90% -123.93% -328.30% -292.49% -206.11% -270.95%
Cash Return on Invested Capital (CROIC)		 -6,912.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -513.78% -601.85% -130.59% -102.77% -73.21% -94.90% -123.93% -328.30% -292.49% -206.11% -270.95%
Return on Equity Simple (ROE_SIMPLE)		 -601.32% 0.00% -262.44% -82.89% -44.91% 0.00% -69.92% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -25 -30 -42 -41 -46 -47 -398 -164 -157 -137
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -6.27% -10.18% -13.88% -10.95% -5.48% -6.12% -7.70% -64.05% -19.34% -10.96% -10.99%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.26% - - - -11.81% -13.59% -153.37% -85.27% -23.90% -25.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -21 -36 -43 -60 -56 -66 -63 -568 -234 -225 -189
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -36 -44 -62 -59 -63 -66 -569 -234 -228 -194
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 13.13 23.54 65.71 28.07 36.23 33.85 41.33 60.92 79.82 19.76 26.93
Price to Tangible Book Value (P/TBV)		 13.37 24.13 68.62 28.34 36.40 34.01 41.56 61.40 80.66 19.82 27.03
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2,778.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.01 1.29 2.26 0.51 0.06 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 1.29 2.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.95 -1.08 -1.12 -1.08 -1.05 -1.07 -1.08 -1.15 -1.11 -1.08 -1.08
Leverage Ratio		 1.61 4.24 2.43 1.84 1.34 1.37 1.44 1.47 1.21 1.13 1.16
Compound Leverage Factor		 1.61 5.60 2.43 1.84 1.34 1.56 1.44 1.47 1.21 1.08 1.16
Debt to Total Capital		 50.16% 56.28% 69.34% 33.89% 5.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 50.16% 0.00% 0.00% 33.89% 5.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 56.28% 69.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 49.84% 43.72% 30.66% 66.11% 94.70% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.17 -0.16 -0.86 -0.62 -0.12 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.17 0.14 0.49 1.40 2.32 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.16 -0.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.24 -0.23 -1.24 -0.90 -0.18 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.24 0.20 0.71 2.03 3.36 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.23 -1.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.62 2.32 5.08 17.97 144.07 165.32 212.04 133.96 119.34 80.39 81.20
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.80 9.30 6.97 2.35 8.31 10.15 10.63 5.13 3.80 9.87 7.41
Quick Ratio		 1.75 9.13 6.68 2.32 8.25 9.88 10.36 4.94 3.67 9.77 7.19
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.50 -24 -25 -6.43 -16 -31 -42 -390 -142 -126 -101
Operating Cash Flow to CapEx		 -28,107.55% -972,950.00% -753,350.00% -52,384.13% -52,236.21% -347,664.29% -14,494.79% 0.00% -131,098.59% -62,157.32% -49,914.69%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.43 -8.55 -13 -31 -25 -24 -17 -39 -47 -55 -53
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -11 -0.91 -4.34 -35 -25 -15 -4.52 -8.04 -22 -31 -36
Enterprise Value (EV)		 1,206 1,743 2,848 5,250 15,405 12,747 13,868 15,506 15,108 12,307 14,102
Market Capitalization		 1,305 1,829 2,905 5,475 15,867 13,160 14,230 15,804 15,347 13,020 14,701
Book Value per Share		 $0.14 $0.11 $0.06 $0.28 $0.60 $0.53 $0.47 $0.35 $0.26 $0.89 $0.70
Tangible Book Value per Share		 $0.14 $0.11 $0.06 $0.28 $0.60 $0.52 $0.46 $0.35 $0.26 $0.88 $0.70
Total Capital		 199 178 144 295 462 389 344 259 192 659 546
Total Debt		 100 100 100 100 25 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 100 100 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -99 -86 -57 -226 -463 -413 -362 -298 -239 -714 -599
Capital Expenditures (CapEx)		 0.05 0.00 0.00 0.06 0.06 0.01 0.42 0.00 0.07 0.16 0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.74 -17 -17 -37 -31 -31 -26 -49 -57 -66 -66
Debt-free Net Working Capital (DFNWC)		 191 169 140 289 456 382 336 249 182 647 533
Net Working Capital (NWC)		 91 169 140 189 431 382 336 249 182 647 533
Net Nonoperating Expense (NNE)		 6.92 11 14 19 15 15 16 168 68 62 53
Net Nonoperating Obligations (NNO)		 -99 -86 -57 -226 -463 -413 -362 -298 -239 -714 -599
Total Depreciation and Amortization (D&A)		 1.22 -0.18 -0.38 -1.59 -2.90 2.37 -2.94 -0.99 0.04 -2.98 -4.17
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.03) $0.49 ($0.06) ($0.09) ($0.08) ($0.08) ($0.09) ($0.76) ($0.31) ($0.28) ($0.24)
Adjusted Weighted Average Basic Shares Outstanding		 697.74M 619.65M 701.79M 707.90M 726.66M 718.54M 738.08M 742.62M 743.42M 747.70M 775.46M
Adjusted Diluted Earnings per Share		 ($0.03) $0.49 ($0.06) ($0.09) ($0.08) ($0.08) ($0.09) ($0.76) ($0.31) ($0.28) ($0.24)
Adjusted Weighted Average Diluted Shares Outstanding		 697.74M 619.65M 701.79M 707.90M 726.66M 718.54M 738.08M 742.62M 743.42M 747.70M 775.46M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 700.84M 701.70M 701.98M 724.54M 737.45M 737.68M 742.67M 742.85M 744.44M 775.37M 776.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -25 -30 -42 -41 -46 -47 -398 -164 -157 -137
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.10% -0.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Summit Therapeutics (SMMT) quarterly financials for the last four years (2022–2025), focused on trends in income statements, cash flows, and balance sheets. The bullets are organized with positives first, then neutral items, then negatives.

  • Large equity financing in 2025-Q4: Issuance of Common Equity was about $573.8 million, and net cash from financing activities in the quarter was also ~$573.8 million, significantly boosting liquidity.
  • Strong liquidity in 2025-Q3: Cash & Equivalents stood at about $238.6 million, providing runway for ongoing operations and R&D efforts.
  • No near-term debt burden: Long-term debt was essentially zero in 2025-Q3, reducing near-term cash obligations and interest costs.
  • Material equity base in play: Total Common Equity was about $192.3 million as of 2025-Q3, giving the company a meaningful balance-sheet cushion to fund ongoing losses and development activities.
  • Q4 2025 financing offsetting operational losses: The sizable equity financing in 2025-Q4 contributed a substantial inflow that offset cash burn from operations, supporting liquidity headroom.
  • Minimal reported revenue over the four-year window: Across multiple quarters, Total Revenue is reported as 0.0, indicating the company is in an early-stage or pre-revenue phase.
  • Dilution risk via equity: Shares outstanding are in the mid-to-high 700 millions range (roughly 742–775 million across 2025 periods), which could dilute existing holders if additional equity is issued.
  • Profits remain negative: Net income across recent quarters is deeply negative (for example, -$219.172 million in 2025-Q4 and -$231.793 million in 2025-Q3 continuing operations).
  • Ongoing cash burn from operations: Net cash from continuing operating activities was -$101.9 million in 2025-Q4 and -$93.1 million in 2025-Q3, highlighting sustained cash burn from operations despite financing inflows.
  • Significant investing outflows: Net cash from investing activities was heavily negative in periods like 2025-Q4 (around -$484.993 million), reflecting substantial investments and asset allocations that reduce cash despite financing support.
05/14/26 03:51 PM ETAI Generated. May Contain Errors.

Summit Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Summit Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Summit Therapeutics' net income appears to be on an upward trend, with a most recent value of -$1.08 billion in 2025, rising from -$29.06 million in 2016. The previous period was -$221.32 million in 2024. Check out Summit Therapeutics' forecast to explore projected trends and price targets.

Summit Therapeutics' total operating income in 2025 was -$1.09 billion, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $1.09 billion

Over the last 9 years, Summit Therapeutics' total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

Summit Therapeutics' total liabilities were at $92.32 million at the end of 2025, a 97.2% increase from 2024, and a 77.5% increase since 2017.

In the past 8 years, Summit Therapeutics' cash and equivalents has ranged from $28.67 million in 2018 to $348.61 million in 2022, and is currently $225.27 million as of their latest financial filing in 2025.

Over the last 9 years, Summit Therapeutics' book value per share changed from 0.00 in 2016 to 0.89 in 2025, a change of 88.5%.


Related Companies

Financial statements for NASDAQ:SMMT last updated on 5/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump is positioned. Elon lights the fuse.
Bitcoin is back above $80,000. Altcoins are pumping. ETF inflows are accelerating. The CLARITY Act… the most b...
Crypto 101 Media | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Distracted Americans set to miss out on quadrillions
Technology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...
Brownstone Research | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel